Annals of Surgical Oncology

, Volume 21, Issue 6, pp 1853–1861 | Cite as

Patients with CD133-Negative Colorectal Liver Metastasis Have a Poor Prognosis After Hepatectomy

  • Shinya Yamamoto
  • Kuniya TanakaEmail author
  • Kazuhisa Takeda
  • Hirotoshi Akiyama
  • Yasushi Ichikawa
  • Yoji Nagashima
  • Itaru Endo
Hepatobiliary Tumors



The prognostic factors for patients with colorectal cancer liver metastasis (L-Mets) have not been fully described.


Resected specimens were obtained surgically from 1998 to 2008 at our university hospital. We investigated whether the status of two primary lesion cancer stem biomarkers, CD44 and CD133, were maintained in L-Mets and whether these markers were L-Mets prognostic factors. To investigate the CD133 and CD44 status, proliferation, invasiveness, and chemoresistance were examined immunohistochemically by using MIB-1, E-cadherin, and ABC-G2.


The CD44-positive rate in primary lesions and L-Mets was 41.4 and 58.7 %, respectively. There was no correlation of CD44 expression between primary lesions and L-Mets (r = 0.250, p = 0.071). The CD133-positive rate in primary lesions and L-Mets was 53.6 and 44.6 %, respectively. There was no correlation of CD133 expression between primary lesions and L-Mets (r = 0.219, p = 0.135). In the CD133-negative group, the MIB-1 index was significantly higher than in the CD133-positive group (61.6 vs. 46.3 %, p = 0.003), and E-cadherin expression was significantly lower in the CD133-negative group compared with the CD133-positive group (29.3 vs. 46.8 %, p = 0.001). Absence of CD133 expression in L-Mets correlated with poor overall survival (p = 0.006), and multivariate regression analysis showed that it was an independent marker for poor survival (hazard ratio 0.320, p = 0.0016).


The absence of CD133 expression in L-Mets was an independent marker and a poor prognostic factor, possibly because of increased proliferation and invasiveness.


CD133 Expression Metastatic Lesion Primary Lesion Cancer Stem Cell Marker Tumor Doubling Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



None of the authors have any commercial interest associated with this study.


  1. 1.
    Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16:452–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.PubMedCrossRefGoogle Scholar
  5. 5.
    Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Vermaat JS, Nijman IJ, Koudijs MJ, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 2012;18:688–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence in Tissues Study (BRITS). Breast Cancer Res. 2010;12:R92.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Kobayashi H, Sugihara K, Uetake H, et al. Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol. 2009;34:1147–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Nadal R, Ortega FG, Salido M, et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer. 2013;133:2398–407.PubMedCrossRefGoogle Scholar
  11. 11.
    Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg. 2004;28:263–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang Q, Chen ZG, Du CZ, et al. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 2009;55:284–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Wakamatsu Y, Sakamoto N, Oo HZ, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012;62:112–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Fan L, He F, Liu H, et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 2011;11:320.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Kobayashi S, Yamada-Okabe H, Suzuki M, et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells. 2012;30:2631–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim HJ, Kim MJ, Ahn SH, et al. Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast. 2011;20:78–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120:1444–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Brescia P, Ortensi B, Fornasari L, et al. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013;31:857–69.PubMedCrossRefGoogle Scholar
  21. 21.
    Wen L, Chen XZ, Yang K, et al. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One. 2013;8:e59154.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Mizugaki H, Sakakibara-Konishi J, Kikuchi J, et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2013;39:1070–81.Google Scholar
  23. 23.
    Ahmed MA, Aleskandarany MA, Rakha EA, et al. A CD44(−)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat. 2012;133:979–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Poplawski AB, Jankowski M, Erickson SW, et al. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur J Hum Genet. 2010;18:560–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, et al. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON. 2012;17:277–83.PubMedGoogle Scholar
  26. 26.
    Goranova TE, Ohue M, Shimoharu Y, Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis. 2011;28:427–35.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285–9.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111–20.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010;10:218.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Hentic O, Couvelard A, Rebours V, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer. 2011;18:51–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen X, Wang Y, Xia H, et al. Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Mol Biol Rep. 2012;39:6707–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Wu Q, Guo R, Lin M, et al. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol. 2011;122:149–54.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu HG, Pan YF, You J, et al. Expression of ABCG2 and its significance in colorectal cancer. Asian Pac J Cancer Prev. 2010;11:845–8.PubMedGoogle Scholar
  35. 35.
    Sodani K, Tiwari AK, Singh S, et al. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 2012;83:1613–22.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281–90.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel). 2011;3:716–29.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Ma XL, Xiao ZL, Liu L, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev. 2012;13:1137–44.PubMedCrossRefGoogle Scholar
  40. 40.
    Pilati P, Mocellin S, Bertazza L, et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol. 2012;19:402–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Shinya Yamamoto
    • 1
  • Kuniya Tanaka
    • 1
    Email author
  • Kazuhisa Takeda
    • 1
  • Hirotoshi Akiyama
    • 1
  • Yasushi Ichikawa
    • 1
  • Yoji Nagashima
    • 2
  • Itaru Endo
    • 1
  1. 1.Department of Gastroenterological SurgeryYokohama City University Graduate School of MedicineYokohamaJapan
  2. 2.Department of PathologyYokohama City University Graduate School of MedicineYokohamaJapan

Personalised recommendations